MAP3K19 Is a Novel Regulator of TGF- _ Signaling That Impacts Bleomycin-Induced Lung Injury and Pulmonary Fibrosis.

DSpace Repository

Show simple item record

dc.contributor.author Boehme, Stefen A
dc.contributor.author Franz-Bacon, Karin
dc.contributor.author DiTirro, Danielle N
dc.contributor.author Ly, Tai Wei
dc.contributor.author Bacon, Kevin B
dc.date.accessioned 2019-01-29T18:18:29Z
dc.date.available 2019-01-29T18:18:29Z
dc.date.issued 2016
dc.identifier.issn 1932-6203
dc.identifier.other PMC4856290
dc.identifier.uri https://hdl.handle.net/10192/36395
dc.description.abstract Idiopathic pulmonary fibrosis (IPF) is a progressive, debilitating disease for which two medications, pirfenidone and nintedanib, have only recently been approved for treatment. The cytokine TGF- _ has been shown to be a central mediator in the disease process. We investigated the role of a novel kinase, MAP3K19, upregulated in IPF tissue, in TGF- _-induced signal transduction and in bleomycin-induced pulmonary fibrosis. MAP3K19 has a very limited tissue expression, restricted primarily to the lungs and trachea. In pulmonary tissue, expression was predominantly localized to alveolar and interstitial macrophages, bronchial epithelial cells and type II pneumocytes of the epithelium. MAP3K19 was also found to be overexpressed in bronchoalveolar lavage macrophages from IPF patients compared to normal patients. Treatment of A549 or THP-1 cells with either MAP3K19 siRNA or a highly potent and specific inhibitor reduced phospho-Smad2 & 3 nuclear translocation following TGF- _ stimulation. TGF- _-induced gene transcription was also strongly inhibited by both the MAP3K19 inhibitor and nintedanib, whereas pirfenidone had a much less pronounced effect. In combination, the MAP3K19 inhibitor appeared to act synergistically with either pirfenidone or nintedanib, at the level of target gene transcription or protein production. Finally, in an animal model of IPF, inhibition of MAP3K19 strongly attenuated bleomycin-induced pulmonary fibrosis when administered either prophylactically ortherapeutically. In summary, these results strongly suggest that inhibition of MAP3K19 may have a beneficial therapeutic effect in the treatment of IPF and represents a novel strategy to target this disease.
dc.format.extent 1 file
dc.language English
dc.language.iso eng
dc.publisher Public Library of Science
dc.relation.isversionof https://dx.doi.org/10.1371/journal.pone.0154874
dc.rights Creative Commons Attribution 4.0 International License
dc.rights.uri http://creativecommons.org/licenses/by/4.0/
dc.subject A549 Cells
dc.subject Animals
dc.subject Bleomycin
dc.subject Bronchoalveolar Lavage
dc.subject Cell Line, Tumor
dc.subject Disease Models, Animal
dc.subject Epithelial Cells
dc.subject Female
dc.subject HeLa Cells
dc.subject Humans
dc.subject Idiopathic Pulmonary Fibrosis
dc.subject Indoles
dc.subject Lung
dc.subject Lung Injury
dc.subject MAP Kinase Kinase Kinases
dc.title MAP3K19 Is a Novel Regulator of TGF- _ Signaling That Impacts Bleomycin-Induced Lung Injury and Pulmonary Fibrosis.
dc.type Article
dc.contributor.department Department of Biology
dc.relation.journal PloS One
dc.identifier.pmid 27144281


Files in this item

This item appears in the following Collection(s)

Show simple item record

Creative Commons Attribution 4.0 International License Except where otherwise noted, this item's license is described as Creative Commons Attribution 4.0 International License

Search BIR


Browse

My Account